Glaukos (NYSE:GKOS) Price Target Lowered to $175.00 at Mizuho

Glaukos (NYSE:GKOS - Free Report) had its price target cut by Mizuho from $200.00 to $175.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the medical instruments supplier's stock.

GKOS has been the subject of several other research reports. Needham & Company LLC upped their price objective on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler cut their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. Truist Financial cut their price objective on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company boosted their price objective on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus upped their price target on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $156.17.

Glaukos Stock Performance

Shares of NYSE:GKOS traded down $2.09 during trading on Wednesday, reaching $88.17. 772,039 shares of the company's stock traded hands, compared to its average volume of 898,508. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a 50 day moving average of $108.10 and a 200-day moving average of $131.41. The stock has a market capitalization of $4.99 billion, a P/E ratio of -30.72 and a beta of 0.88. Glaukos has a 12 month low of $77.91 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, equities analysts expect that Glaukos will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Glaukos

Large investors have recently bought and sold shares of the company. Avior Wealth Management LLC grew its holdings in Glaukos by 30.1% during the 1st quarter. Avior Wealth Management LLC now owns 3,384 shares of the medical instruments supplier's stock worth $333,000 after acquiring an additional 782 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Glaukos by 27.5% during the first quarter. Exchange Traded Concepts LLC now owns 6,626 shares of the medical instruments supplier's stock worth $652,000 after buying an additional 1,430 shares during the last quarter. Elevation Point Wealth Partners LLC boosted its stake in Glaukos by 78.2% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 3,221 shares of the medical instruments supplier's stock valued at $317,000 after purchasing an additional 1,413 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in Glaukos by 25.2% during the 1st quarter. Handelsbanken Fonder AB now owns 18,400 shares of the medical instruments supplier's stock worth $1,811,000 after acquiring an additional 3,700 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Glaukos by 35.2% during the first quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier's stock worth $485,000 after purchasing an additional 1,283 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.